NasdaqGS:AMPHPharmaceuticals
Should Amphastar’s (AMPH) Exclusive 10-Year BAQSIMI Deal in Greater China Prompt Investor Action?
Amphastar Pharmaceuticals recently announced an exclusive 10-year distribution agreement with Nanjing Chengong Pharmaceutical to market its BAQSIMI nasal powder product across Mainland China, Taiwan, Hong Kong, and Macau.
This deal expands Amphastar’s access to the Greater China region while highlighting a related party transaction reviewed and approved by independent company directors.
We'll examine how this exclusive arrangement for BAQSIMI in Greater China could reshape Amphastar's...